We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in DexCom (DXCM - Free Report) ten years ago? It may not have been easy to hold on to DXCM for all that time, but if you did, how much would your investment be worth today?
DexCom's Business In-Depth
With that in mind, let's take a look at DexCom's main business drivers.
San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.
According to an article by Mordor Intelligence, the CGM devices market is expected to witness a CAGR of nearly 12.9% between 2021 and 2029, with strong growth in the Asia Pacific region. The market is expected to reach $21.34 billion in 2029.
DexCom’s product portfolio consists of CGM devices targeting type 1 and type 2 diabetes patients. The company received FDA approval for its first product in 2006 and has continued to add upgraded devices to its portfolio. The company currently focuses on its latest generation systems, the Dexcom G6 (2018 approval) and G7 (2023 approval) integrated CGM (iCGM) devices. Apart from these iCGM products, the company has DexCom One and One+ sensors offering similar capabilities like G6 and G7 except for integration of digitally connected devices, including automated insulin dosing systems. The company markets One (approval 2022) and One+ (approval 2024) sensors only in Europe. While G6 & G7 sensors are approved for use in any type 1 or 2 diabetic patient above two years of age, One & One+ sensors are approved for use in similar patient populations but using insulin. The company received approval for its first OTC glucose sensor, Stelo, in March 2024, for use in type 2 diabetic patients.
However, market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions.
2025 at a Glance
For the full-year 2025, the company reported adjusted EPS of $2.09, up 27.4% from 2022. Full-year 2025 revenues came in at $4.66 billion, up 16% year over year.
DexCom generated nearly 85.4% of revenues from its distributors and the rest from direct sale during the fourth quarter of 2025. In the fourth quarter, U.S. sales increased 11% to $891.5 million (70.1% of total revenue) while international sales improved 18.5% to $310.7 million (29.9% of total revenue).
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in DexCom a decade ago, you're probably feeling pretty good about your investment today.
A $1000 investment made in August 2016 would be worth $4,012.02, or a gain of 301.20%, as of August 13, 2026, according to our calculations. This return excludes dividends but includes price appreciation.
In comparison, the S&P 500's gained 254.78% and the price of gold went up 214.97% over the same time frame.
Looking ahead, analysts are expecting more upside for DXCM.
DexCom's second-quarter performance reflects a balanced mix of durable CGM growth drivers and manageable execution risks. The G7 15 Day rollout, steady U.S. new-patient gains and stronger international access support continued revenue momentum, while positive CONNECT data may strengthen the case for broader type 2 coverage. Stelo's redesigned app and AI-led insights add an option in consumer metabolic health, and manufacturing, freight and platform efficiencies are lifting profitability even as DexCom invests in Ireland capacity. At the same time, the market remains highly competitive, with pricing, rebates and channel mix capable of pressuring growth. Foreign exchange is a modest drag, and the transition away from G6 brings inventory and execution costs. Litigation and product-related claims add uncertainty.
Over the past four weeks, shares have rallied 24.84%, and there have been 10 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in DexCom (DXCM - Free Report) ten years ago? It may not have been easy to hold on to DXCM for all that time, but if you did, how much would your investment be worth today?
DexCom's Business In-Depth
With that in mind, let's take a look at DexCom's main business drivers.
San Diego, CA-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.
According to an article by Mordor Intelligence, the CGM devices market is expected to witness a CAGR of nearly 12.9% between 2021 and 2029, with strong growth in the Asia Pacific region. The market is expected to reach $21.34 billion in 2029.
DexCom’s product portfolio consists of CGM devices targeting type 1 and type 2 diabetes patients. The company received FDA approval for its first product in 2006 and has continued to add upgraded devices to its portfolio. The company currently focuses on its latest generation systems, the Dexcom G6 (2018 approval) and G7 (2023 approval) integrated CGM (iCGM) devices. Apart from these iCGM products, the company has DexCom One and One+ sensors offering similar capabilities like G6 and G7 except for integration of digitally connected devices, including automated insulin dosing systems. The company markets One (approval 2022) and One+ (approval 2024) sensors only in Europe. While G6 & G7 sensors are approved for use in any type 1 or 2 diabetic patient above two years of age, One & One+ sensors are approved for use in similar patient populations but using insulin. The company received approval for its first OTC glucose sensor, Stelo, in March 2024, for use in type 2 diabetic patients.
However, market for blood glucose monitoring devices is highly competitive, subject to rapid change and significantly affected by new product introductions.
2025 at a Glance
For the full-year 2025, the company reported adjusted EPS of $2.09, up 27.4% from 2022. Full-year 2025 revenues came in at $4.66 billion, up 16% year over year.
DexCom generated nearly 85.4% of revenues from its distributors and the rest from direct sale during the fourth quarter of 2025. In the fourth quarter, U.S. sales increased 11% to $891.5 million (70.1% of total revenue) while international sales improved 18.5% to $310.7 million (29.9% of total revenue).
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in DexCom a decade ago, you're probably feeling pretty good about your investment today.
A $1000 investment made in August 2016 would be worth $4,012.02, or a gain of 301.20%, as of August 13, 2026, according to our calculations. This return excludes dividends but includes price appreciation.
In comparison, the S&P 500's gained 254.78% and the price of gold went up 214.97% over the same time frame.
Looking ahead, analysts are expecting more upside for DXCM.
DexCom's second-quarter performance reflects a balanced mix of durable CGM growth drivers and manageable execution risks. The G7 15 Day rollout, steady U.S. new-patient gains and stronger international access support continued revenue momentum, while positive CONNECT data may strengthen the case for broader type 2 coverage. Stelo's redesigned app and AI-led insights add an option in consumer metabolic health, and manufacturing, freight and platform efficiencies are lifting profitability even as DexCom invests in Ireland capacity. At the same time, the market remains highly competitive, with pricing, rebates and channel mix capable of pressuring growth. Foreign exchange is a modest drag, and the transition away from G6 brings inventory and execution costs. Litigation and product-related claims add uncertainty.
Over the past four weeks, shares have rallied 24.84%, and there have been 10 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.